Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 10, 237-244
Abstract
No abstract availableKeywords
Funding Information
- Audentes Therapeutics
This publication has 18 references indexed in Scilit:
- Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicityin vivoDisease Models & Mechanisms, 2014
- Adeno-Associated Viral Vector Serotype 5 Poorly Transduces Liver in Rat ModelsPLOS ONE, 2013
- Biodistribution of AAV8 Vectors Expressing Human Low-Density Lipoprotein Receptor in a Mouse Model of Homozygous Familial HypercholesterolemiaHuman Gene Therapy Clinical Development, 2013
- Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 VectorHuman Gene Therapy, 2012
- Rescue of bilirubin‐induced neonatal lethality in a mouse model of Crigler‐Najjar syndrome type I by AAV9‐mediated gene transferThe FASEB Journal, 2011
- Disruption of the Ugt1 Locus in Mice Resembles Human Crigler-Najjar Type I DiseaseJournal of Biological Chemistry, 2008
- Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to LiverMolecular Therapy, 2006
- Adeno-associated Virus Vector Serotypes Mediate Sustained Correction of Bilirubin UDP Glucuronosyltransferase Deficiency in RatsMolecular Therapy, 2006
- Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman PrimatesMolecular Therapy, 2006
- Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathwayBlood, 2003